Oliver Diaz Espinosa, PhD
Senior Research Scientist, Advanced Modeling
Oliver Diaz is a mathematician on the advanced modeling team at PHE. Prior to joining PHE, Oliver was at Blue Cross Blue Shield (BCBS) of Texas. There, he developed statistical procedures and models to infer cost-effectiveness of medical policies in both commercial and government plans; to estimate the financial impact of new drugs; to evaluate the performance of cost-saving initiatives; and to identify business opportunities. Prior to BCBS, Oliver held a joint postdoctoral position at McMaster University and the University of Toronto, followed by visiting research position at the Statistics and Applied Mathematics Sciences Institute (SAMSI) and Duke University.
PhD, Mathematics, University of Texas at Austin
BSc, Actuarial Sciences, National Autonomous University of Mexico
- Frasco MA, et al. Incremental net monetary benefit of ocrelizumab relative to subcutaneous interferon β-1a. J Med Econ. 2017.
- Moreno GA, et al. Value of comprehensive HCV treatment among vulnerable, high-risk populations. Value Health. 2017.
- Sail K, et al. Lifetime costs of patients with chronic lymphocytic leukemia. Blood. 2017.